Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emmanuel Kapesa
Institution:
National Institute for Medical Research
Observed institution:
National Institute for Medical Research
ORCID:
0000-0002-6577-5355
Observed ORCID:
0000-0002-6577-5355
OpenAlex ID:
A5018811709
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
2020
·
Mina C Hosseinipour
, Craig Innes
, et al.
·
Clinical Infectious Diseases
·
35
PDF
Examining oral pre-exposure prophylaxis (PrEP) literacy among participants in an HIV vaccine trial preparedness cohort study
2022
·
Rujeko Samanthia Chimukuche
, Rachel Kawuma
, et al.
·
BMC Health Services Research
·
10
PDF
Facilitators and barriers to implementation of HPV vaccination in Tanzania: a mixed-methods study exploring perspectives from national, subnational, and community stakeholders, 2018–2023
2025
·
Julie Garon Carlton
, Doreen Pamba
, et al.
·
Vaccine
·
6
Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study
2026
·
Rachel Kawuma
, Sarah Nakamanya
, et al.
·
Trials
·
1
Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a, Double-Blinded Randomized Controlled Trial
2026
·
George Peter Judicate
, Marco Missanga
, et al.
·
JMIR Research Protocols
Show more works
View as search
Works count:
5
Citation count:
52
H-index:
3
I10-index:
2
Year
Topic
Type